Release issued 15th March 2002

MONTREAL, Quebec, March 15, 2002 - ConjuChem Inc. (TSE:CJC), developers of the drug-enabling DAC(tm) technology, today announced a sponsored research collaboration agreement with Suntory Pharmaceutical Research Laboratories LLC (SPRL), a drug discovery and development company based in Cambridge MA.

The agreement calls for the application of ConjuChem's in vivo bioconjugation DAC(tm) Technology to create new and longer-acting therapeutic compounds to treat cardiovascular and related diseases.

"This agreement marks our entry into the cardiovascular therapeutic arena," said ConjuChem President and CEO Duffy DuFresne. "The agreement illustrates the scope of potential applications for our DAC(tm) technology and this Company's commitment to pursuing new opportunities to expand our product pipeline."

About Suntory Pharmaceutical Research Laboratories LLC Suntory Pharmaceutical Research Laboratories LLC (SPRL) mission is rapid, cost-effective discovery and development of small molecule drugs for the treatment of cardiovascular and immunological diseases. For more information: http://www.sprlus.com

(8th August 2002) ConjuChem Reports Mixed Preliminary Results from Three DAC(tm):Opioid Trials

(8th August 2002) ConjuChem Discontinues DAC(tm):TI Development

(8th July 2002) ConjuChem Announces Start of Phase I Trial for DAC:GLP-1(TM), a Type 2

(13th May 2002) ConjuChem Announces Results of DAC:Opioid Repeat Dose Immunogenicity Trial

(13th May 2002) ConjuChem Completes Phase I DAC:TI Patient Enrolment